Novartis (NVS)
Novartis Free Cash Flow: 2.268B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NVS Free Cash Flow Rankings
| Overall | 98th percentile | 59 of 4360 |
| Sector | 99th percentile | 4 of 501 in Healthcare |
| Industry | 88th percentile | 3 of 25 in Drug Manufacturers - Major |
NVS Free Cash Flow Range, Past 5 Years
| Minimum | 1.246B | Jun 2007 |
| Maximum | 3.784B | Dec 2009 |
| Average | 2.512B |
About Free Cash Flow
Click "Learn More" below to see how YCharts calculates Free Cash Flow.
Free cash flow is the amount of cash generated by a business that is available for distribution among its security holders. Security holders include debt holders, equity holders, preferred stock holders, and convertible security holders. Specifically, free cash flow is used to pay dividends, make acquisitions, develop new products, invest in new property, plant and equipment, pay interest expenses, and reduce debt.
According to many investors, free cash flow is the best indication of a company's ability to generate cash.
Learn More
You may also be interested in these NVS related companies
NVS News
Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story
May 23, 5:03PM Benzinga
May 23, 5:03PM Benzinga
Perrigo (PRGO) Gets Final FDA Approval for Generic Prevacid Caps (NVS)
May 18, 1:36PM Street Insider
May 18, 1:36PM Street Insider
Novartis (NVS) Updates on Lucentis; Shows Encouraging Results in DME Patients
May 10, 7:45AM Street Insider
May 10, 7:45AM Street Insider
$SQNM 1 competitor down: $NVS : Fluidigm, Novartis End Pact Aimed at Non-invasive Fetal Diagnostic Test $ILMN $GNOM
about 23 days ago by biotech
about 23 days ago by biotech
$NVS FDA approved Afinitor for treatment of adult patients w kidney tumors who do not require immediate surgery. http://stks.co/3XkB
about 34 days ago by abubnic
about 34 days ago by abubnic
News related to $NVS: 'New J&J CEO plans realistic, optimistic future' http://stks.co/3Vvz
about 35 days ago by TradeBot
about 35 days ago by TradeBot
$NVS http://stks.co/3Rts WEEKLY. Breakout appears imminent on this Swiss drug maker. Yields 4.4%
about 39 days ago by dv0x
about 39 days ago by dv0x
@HighRiskBuyer $ARNA $NVS $VNDA $ONXX $DNDN $KERX nothing earlier, Looks like he made up his own false rumors.
about 41 days ago by jackofalltrade
about 41 days ago by jackofalltrade
@natesadeghi Be careful what you focus in on. $AMLN (Byetta & Bydureon) continues to take market share away from Victoza $NVS
about 44 days ago by jackofalltrade
about 44 days ago by jackofalltrade
$TARO shareholders sign this online petition if u agree..will be sent to Taro BOD $TEVA $PFE $NVIV $NVS $AGEN $PRGO http://stks.co/3L8b
about 47 days ago by imhobutdydd
about 47 days ago by imhobutdydd
Quick Pitch: Long on $AZN Target Price: $62 http://stks.co/3Jz7 $SNY $NVS "Best downside protection among Pharma large caps"
about 48 days ago by SumZero
about 48 days ago by SumZero
- $NVS - any ideas on how the recall will affect nvs Q1 earnings repo
about 49 days ago by SCPlunger
about 49 days ago by SCPlunger
Wal-Mart’s Great Dividend Story: Cash Flow Monster Shares the Wealth http://stks.co/3GsC $WMT $AZN $GSK $NVS $MRK $BMY $PFE
about 51 days ago by ycharts
about 51 days ago by ycharts
$IDIX IMHO there won't be possibility of M&A until 184 is proven to work in clinical trials, see $GILD. Only then maybe, if $NVS allows.
about 63 days ago by lindaheart
about 63 days ago by lindaheart
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NVS | 52.00 | -0.26 | -0.49% | 125.77B |
| NVR | 800.47 | -33.73 | -4.04% | 4.221B |
| NVO | 135.80 | -2.83 | -2.04% | 80.41B |
| NVMI | 7.00 | +0.00 | +0.00% | 183.89M |
| NVLS | 42.29 | -1.21 | -2.78% | 3.080B |
| NVJ | 15.54 | -0.05 | -0.30% | |
| NVEC | 51.74 | -1.01 | -1.91% | 254.26M |
| NVE | 17.09 | -0.16 | -0.93% | 4.071B |
| NVDA | 12.54 | -0.18 | -1.42% | 7.857B |
| NVAX | 1.235 | -0.04 | -3.52% | 155.61M |
